TYROSINE KINASE INHIBITOR
Bosulif is a prescription drug approved by the Food and Drug Administration (FDA) to treat adults with chronic myelogenous leukemia (CML) that has tested positive for the Philadelphia chromosome (Ph+). Bosulif is also referred to by its drug name, Bosutinib.
Bosulif is used as targeted therapy for leukemia. Bosulif is a member of a class of drugs called tyrosine kinase inhibitors. Bosulif is believed to work by inhibiting replication and triggering cell death in leukemia cells.
How do I take it?
Prescribing information states that Bosulif is taken orally once daily.
Bosulif comes in tablet form.
The FDA-approved label for Bosulif lists common side effects including headache, fatigue, fever, cough, nausea, diarrhea, vomiting, abdominal pain, rash, swelling, and low blood cell counts.
Rare but serious side effects listed for Bosulif include fluid retention, fetal harm in pregnant women, and damage to liver, kidneys, or gastrointestinal system.
For more details about this treatment, visit:
Bosulif – Pfizer
CML: Tyrosine Kinase Inhibitor (TKI) Therapy – Leukemia & Lymphoma Society